Supplements

Citicoline: The Doses From 4 Trials, and Who It Actually Helped

·HealthyMag Editorial Team
An amber glass bottle and white capsules on a pale linen cloth in soft daylight

Quick Answer: Citicoline (CDP-choline, sold in US supplements as Cognizin) has two small positive trials in healthy people and two large negative trials in patients. In healthy older adults with age-related memory complaints, 500 mg a day for 12 weeks improved episodic memory and a composite memory score, but those were secondary outcomes: the trial’s primary outcome, a spatial memory test, did not differ significantly from placebo. In 75 healthy adolescent boys, 250 or 500 mg a day for 28 days improved attention (p = 0.02). Both trials were funded by Kyowa Hakko Bio, which makes Cognizin. In patients, citicoline failed in 2,298 people after stroke (ICTUS) and 1,213 people after traumatic brain injury (COBRIT). A Cochrane review found “some evidence” of short-term benefit for memory and behaviour in older people with chronic cerebral disorders, and none for attention.

This page sets out every citicoline dose that has been tested in a large or placebo-controlled trial we could verify, who was in each trial, and what it found, so you can see which result applies to you.

Citicoline: the doses tested, and who each trial helped

TrialWhoDose and lengthResult
Nakazaki 2021100 healthy adults aged 50 to 85 with age-associated memory impairment500 mg a day (Cognizin), 12 weeksPrimary outcome (Spatial Span) not significant between groups; episodic memory and composite memory better than placebo
McGlade 201975 healthy adolescent males250 or 500 mg a day (Cognizin), 28 daysAttention p = 0.02, psychomotor speed p = 0.03 vs placebo
ICTUS 20122,298 patients with moderate-to-severe acute ischaemic stroke2,000 mg a day (IV for 3 days, then oral), 6 weeksStopped for futility; recovery odds ratio 1.03 (p = 0.364)
COBRIT 20121,213 patients with traumatic brain injury2,000 mg a day, 90 daysNo difference; favourable recovery 35.4% vs 35.6% on placebo
Cochrane 200514 trials in older people with chronic cerebral disordersMixed doses, 20 days to 12 months“Some evidence” for memory and behaviour; no evidence for attention

The pattern is that citicoline has looked best in small, short trials of people without a serious diagnosis, and worst in the two large trials of people with a serious brain injury, even at four times the supplement dose.

What the Cognizin memory trial actually found

The trial most often quoted for citicoline and memory is Nakazaki 2021 in the Journal of Nutrition. One hundred healthy men and women aged 50 to 85 with age-associated memory impairment took 500 mg of Cognizin a day or a placebo for 12 weeks; 99 finished.

The headline results are real. Episodic memory, measured with a paired-associate test, improved more with citicoline than placebo (mean change 0.15 vs 0.06, P = 0.0025), and so did a composite of four memory tests (3.78 vs 0.72, P = 0.0052).

What most write-ups leave out is that both of those were secondary outcomes. The full paper states that “the primary outcome variable was the raw change in Spatial Span scores.” On that measure, the citicoline group improved from its own baseline but the difference from placebo was not significant; the authors describe only “a tendency toward improvement in the citicoline group.” A trial that misses its primary outcome and finds benefits in secondary ones is a reason for a follow-up trial, not a settled answer.

The paper also says the study “was sponsored by Kyowa Hakko Bio Co., Ltd.”, that the company “funded the study and participated in study design”, and that two authors are its employees. The authors list their own limitations, including that “the effects observed may not be generalizable to young adults” and that the sample was 35 men to 65 women.

Attention: one trial in teenage boys

McGlade 2019 gave 75 healthy adolescent males 250 or 500 mg of Cognizin a day, or placebo, for 28 days. The citicoline group showed better attention (p = 0.02) and psychomotor speed (p = 0.03), and a higher weight-adjusted dose predicted better accuracy on an attention task. Two of the authors work for Kyowa Hakko Bio and one for its US arm.

That result sits awkwardly with the Cochrane review of 14 trials in older people, which found “no evidence of a beneficial effect of CDP-choline on attention.” The two groups are very different, so both can be true, but it means the attention claim on supplement labels rests on one small industry-funded trial in teenagers.

The two large trials that found nothing

Citicoline is a prescribed drug in some countries; the Cochrane review calls it frequently prescribed for cognitive impairment in several European countries. The ICTUS paper notes that it “is approved in some countries for the treatment of acute ischaemic stroke,” and the COBRIT paper that it is “approved for use in TBI in 59 countries.” That approval history is why it was tested properly in large trials.

Stroke. ICTUS randomised 2,298 patients with moderate-to-severe acute ischaemic stroke in Spain, Portugal and Germany to citicoline or placebo within 24 hours. They received 1,000 mg every 12 hours, intravenously for three days and then as tablets, for six weeks. The trial was stopped for futility. Global recovery at 90 days was similar (odds ratio 1.03, 95% CI 0.86 to 1.25), and the authors concluded that “citicoline is not efficacious in the treatment of moderate-to-severe acute ischaemic stroke.” It was funded by Ferrer Grupo.

Traumatic brain injury. COBRIT gave 1,213 patients at eight US trauma centres 2,000 mg of citicoline a day or placebo for 90 days. Favourable recovery on the Glasgow Outcome Scale-Extended was 35.4% with citicoline and 35.6% with placebo, and the overall odds ratio was 0.98 (95% CI 0.83 to 1.15). The conclusion was that citicoline “did not result in improvement in functional and cognitive status.”

These trials do not tell you what citicoline does for a healthy person’s memory. They do tell you that the neuroprotection story often attached to it did not hold up when it was tested at scale.

Citicoline and dementia

The 2005 Cochrane review included 14 trials in older people, ranging from subjective memory complaints to vascular dementia. Seven of them lasted only 20 to 30 days. The reviewers found “some evidence that CDP-choline has a positive effect on memory and behaviour in at least the short to medium term,” called for longer trials, and disclosed that the principal reviewer had been an investigator in some of the included studies.

A 2025 meta-analysis compared citicoline head to head with choline alphoscerate (alpha-GPC) in three randomised trials of 358 people with dementia. Alpha-GPC did better on a geriatric clinical rating scale, but there was no significant difference on memory or word-fluency tests.

Citicoline side effects

The trials reported citicoline as well tolerated. In the 12-week Cognizin trial, eight mild adverse events were judged possibly related to the study product, two in the placebo group and six in the citicoline group, and one person on citicoline withdrew because of a headache. ICTUS, with more than 1,100 people on citicoline, reported no significant differences from placebo in safety outcomes or in the rate of adverse events. The Cochrane review concluded that “the drug was well tolerated.”

That safety record comes from trials of up to a year. It does not cover pregnancy, breastfeeding or children outside the one adolescent trial. If you take medication for Parkinson’s disease, blood pressure or mood, ask a pharmacist before adding it.

Citicoline dosage

  • For memory in older adults: 500 mg a day for 12 weeks is the dose in the Cognizin memory trial.
  • For attention: 250 or 500 mg a day for 28 days, from the adolescent trial.
  • Higher doses: 2,000 mg a day was used in both large patient trials, with no benefit, so a higher dose has no trial support for a better result.

Products that combine citicoline with caffeine, bacopa, ginkgo or other herbs have not been tested as combinations in these trials, and some give a daily citicoline dose above 500 mg. Check the label for the citicoline amount per daily serving, not per capsule.

If you want to try the trial protocol: the memory trial used Cognizin citicoline, 500 mg a day for 12 weeks, and its benefits were in secondary measures, not the primary one. If you try it, run the full 12 weeks and judge it by a memory task you can repeat, not by how you feel in the first week. Cognizin citicoline capsules (Amazon)

Disclosure: Amazon affiliate link; HealthyMag earns a small commission on qualifying purchases at no extra cost to you. We point at single-ingredient citicoline at the tested strength because that is what the trial measured; blends with other actives were not tested.

What the evidence adds up to

Citicoline is not a dead end, but it is a thinner story than its marketing. In healthy people, the support is two small trials, both funded by the company that makes Cognizin, one of which missed its own primary outcome. In serious brain injury, the two largest trials found no benefit at 2,000 mg a day. If you are an older adult worried about memory, a 12-week trial of 500 mg a day matches the best evidence there is. Memory problems that are new, worsening or affecting daily life need a doctor’s assessment first, because several causes are treatable.

Frequently Asked Questions

What is citicoline?

Citicoline is a supplement form of CDP-choline (cytidine diphosphocholine), a compound the body uses to build cell membranes. It is a prescription drug for stroke or brain injury in some countries and a dietary supplement in the US, where the best-known branded form is Cognizin, made by Kyowa Hakko Bio.

What are the benefits of citicoline?

The best evidence is for memory in older adults with age-related memory complaints: 500 mg a day for 12 weeks improved episodic and composite memory in a 100-person trial, though not its primary spatial memory outcome. A 75-person trial in teenage boys found better attention after 28 days. Large trials in stroke (2,298 patients) and brain injury (1,213 patients) found no benefit.

How much citicoline should I take per day?

The healthy-volunteer trials used 250 to 500 mg a day. The memory trial in older adults used 500 mg a day for 12 weeks. Doses of 2,000 mg a day were used in patient trials and did not produce better results.

What are the side effects of citicoline?

Trials describe it as well tolerated. In the 12-week Cognizin trial, six mild events in the citicoline group and two in the placebo group were judged possibly related, and one person stopped because of a headache. The large stroke trial found no significant difference in adverse events from placebo.

Is Cognizin the same as citicoline?

Yes. Cognizin is Kyowa Hakko Bio’s branded citicoline. Both healthy-volunteer trials on this page used it, and both were funded by the company.

Is citicoline better than alpha-GPC?

For dementia, a 2025 meta-analysis of three trials (358 people) found alpha-GPC did better on a clinical rating scale, with no difference on memory or word-fluency tests. No trial we found has compared the two in healthy adults.

Does citicoline help after a stroke?

The largest trial says no. ICTUS randomised 2,298 patients with moderate-to-severe ischaemic stroke and was stopped for futility, with recovery at 90 days the same as placebo (odds ratio 1.03).

Sources

  1. Nakazaki E, Mah E, Sanoshy K, Citrolo D, Watanabe F. Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. J Nutr. 2021;151(8):2153-2160. PubMed 33978188; full text PMC8349115. 100 adults aged 50-85 with AAMI, 99 completed; 500 mg/d for 12 weeks; paired associates 0.15 vs 0.06, P = 0.0025; composite memory 3.78 vs 0.72, P = 0.0052; primary outcome Spatial Span not significant between groups; 6 vs 2 possibly related mild adverse events; sponsored by Kyowa Hakko Bio. NCT03369925. Checked 11 November 2026.
  2. McGlade E, Agoston AM, DiMuzio J, et al. The Effect of Citicoline Supplementation on Motor Speed and Attention in Adolescent Males. J Atten Disord. 2019. PubMed 26179181. 75 males, 250 or 500 mg for 28 days (n = 51) vs placebo (n = 24); attention p = 0.02, psychomotor speed p = 0.03; Kyowa Hakko authors. Abstract. Checked 11 November 2026.
  3. Dávalos A, Alvarez-Sabín J, Castillo J, et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet. 2012;380(9839):349-57. PubMed 22691567. 2,298 patients (1,148 citicoline, 1,150 placebo); 1,000 mg every 12 h for 6 weeks; stopped for futility; OR 1.03 (95% CI 0.86-1.25), p = 0.364; funded by Ferrer Grupo. Abstract. Checked 11 November 2026.
  4. Zafonte RD, Bagiella E, Ansel BM, et al. Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT). JAMA. 2012;308(19):1993-2000. PubMed 23168823. 1,213 patients, 2,000 mg/d for 90 days; GOS-E favourable 35.4% vs 35.6%; global OR 0.98 (95% CI 0.83-1.15). Abstract. Checked 11 November 2026.
  5. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev. 2005;(2):CD000269. PubMed 15846601. 14 studies; 7 lasted 20-30 days; no evidence of benefit on attention; some evidence for memory and behaviour; principal reviewer was an investigator in some included studies. Abstract. Checked 11 November 2026.
  6. Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis. Front Neurol. 2025. PubMed 41426989. 3 RCTs, 358 participants; SCAG WMD -3.92 (95% CI -7.41 to -0.42) favouring choline alphoscerate; no difference on memory or word fluency. Abstract. Checked 11 November 2026.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making any health decisions. Content reviewed by the HealthyMag Editorial Team.

Related